Atglistatin - Preclinical development of small molecule inhibitors targeting human adipose triglyceride lipase

Obesity and obesity-related metabolic diseases represent a major health threat in the 21st century. Over the last decades the prevalence of obesity, type-2 diabetes, and non-alcoholic fatty liver diseases (NAFLD) has increased at terrifying rates. Estimates by the Worl Health Organization in 2014 assume that more than 1.9 billion adults are overweight and more than 600 million are obese (BMI>30). This accounts for 39% of the adult world population. The project aims for the development of a new anti-diabetic, lipid-reducing, anti-steaotic drug.